Perceptive Advisors’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
VPM
VCM
DTC
Perceptive Advisors's AXSM Position: Q1 2026 in Review
Perceptive Advisors increased its Axsome Therapeutics (AXSM) stake by 0.71% in Q1 2026, buying an estimated $181K and bringing the position to 149,950 shares worth $25.3M. The position accounts for 0.5% of the portfolio, ranked #44.
Perceptive Advisors first reported a position in AXSM in Q1 2019 and has held it in 19 quarters since. The position peaked at $88.2M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Perceptive Advisors held 149,950 shares of Axsome Therapeutics worth $25.3M as of Q1 2026.
- Perceptive Advisors bought 1,050 Axsome Therapeutics shares in Q1 2026, an estimated $181K.
- Axsome Therapeutics made up 0.5% of Perceptive Advisors's portfolio in Q1 2026, its #44 holding.
- Perceptive Advisors first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 19 quarters since.
- Perceptive Advisors's Axsome Therapeutics position peaked at $88.2M in Q1 2024.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.